{"id":"https://openalex.org/W204020518","doi":null,"title":"Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.","display_name":"Emerging efficacy endpoints for targeted therapies in advanced renal cell carcinoma.","publication_year":2006,"publication_date":"2006-05-01","ids":{"openalex":"https://openalex.org/W204020518","mag":"204020518","pmid":"https://pubmed.ncbi.nlm.nih.gov/16773841"},"language":"en","primary_location":{"id":"pmid:16773841","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16773841","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology (Williston Park, N.Y.)","raw_type":"Journal Article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113897043","display_name":"Martin Eric Gore","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I125671874","display_name":"National Health Service","ror":"https://ror.org/02wnqcb97","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I125671874","https://openalex.org/I1311074006"]},{"id":"https://openalex.org/I1325846038","display_name":"Royal Marsden NHS Foundation Trust","ror":"https://ror.org/0008wzh48","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038"]},{"id":"https://openalex.org/I4210121186","display_name":"Royal Marsden Hospital","ror":"https://ror.org/034vb5t35","country_code":"GB","type":"healthcare","lineage":["https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Martin E Gore","raw_affiliation_strings":["Department of Medicine, The Royal Marsden Hospital (NHS Trust), London, England. Martin.Gore@rmh.nhs.uk"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Medicine, The Royal Marsden Hospital (NHS Trust), London, England. Martin.Gore@rmh.nhs.uk","institution_ids":["https://openalex.org/I125671874","https://openalex.org/I1325846038","https://openalex.org/I4210121186"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5049672639","display_name":"Bernard J. Escudier","orcid":"https://orcid.org/0000-0002-4626-0479","observed_orcids":["https://orcid.org/0000-0002-4626-0479"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bernard Escudier","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.5538,"has_fulltext":false,"cited_by_count":23,"citation_normalized_percentile":{"value":0.92489863,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":93},"biblio":{"volume":"20","issue":"6 Suppl 5","first_page":"19","last_page":"24"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10449","display_name":"Renal cell carcinoma treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10458","display_name":"Bladder and Urothelial Cancer Treatments","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2746","display_name":"Surgery"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10073","display_name":"Hepatocellular Carcinoma Treatment and Prognosis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2721","display_name":"Hepatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/advanced-renal-cell-carcinoma","display_name":"advanced renal cell carcinoma","score":0.9789999723434448},{"id":"https://openalex.org/keywords/targeted-therapy","display_name":"targeted therapy","score":0.8930000066757202},{"id":"https://openalex.org/keywords/efficacy-endpoints","display_name":"efficacy endpoints","score":0.8050000071525574},{"id":"https://openalex.org/keywords/sorafenib","display_name":"sorafenib","score":0.878000020980835},{"id":"https://openalex.org/keywords/multikinase-inhibitor","display_name":"multikinase inhibitor","score":0.906000018119812},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8640000224113464},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9879999756813049},{"id":"https://openalex.org/keywords/tumor-response-rate","display_name":"tumor response rate","score":0.843999981880188},{"id":"https://openalex.org/keywords/clinical-benefit","display_name":"clinical benefit","score":0.6309999823570251},{"id":"https://openalex.org/keywords/biomarkers","display_name":"biomarkers","score":0.6449999809265137}],"concepts":[{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.9215710759162903},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8466152548789978},{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.8385524749755859},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.7128410339355469},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6476874351501465},{"id":"https://openalex.org/C207103383","wikidata":"https://www.wikidata.org/wiki/Q3930246","display_name":"Hazard ratio","level":3,"score":0.5848140716552734},{"id":"https://openalex.org/C61943457","wikidata":"https://www.wikidata.org/wiki/Q6046661","display_name":"Interim analysis","level":3,"score":0.5479044318199158},{"id":"https://openalex.org/C2781230642","wikidata":"https://www.wikidata.org/wiki/Q492646","display_name":"Targeted therapy","level":3,"score":0.5477860569953918},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.5248822569847107},{"id":"https://openalex.org/C141341695","wikidata":"https://www.wikidata.org/wiki/Q2368661","display_name":"Surrogate endpoint","level":2,"score":0.4333561062812805},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4311119019985199},{"id":"https://openalex.org/C2780739268","wikidata":"https://www.wikidata.org/wiki/Q2112244","display_name":"Progression-free survival","level":3,"score":0.4246048927307129},{"id":"https://openalex.org/C2777546739","wikidata":"https://www.wikidata.org/wiki/Q33525","display_name":"Carcinoma","level":2,"score":0.4176715612411499},{"id":"https://openalex.org/C3019894029","wikidata":"https://www.wikidata.org/wiki/Q332823","display_name":"Overall survival","level":2,"score":0.2980293035507202},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.1744396686553955},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.13658499717712402}],"mesh":[{"descriptor_ui":"D000077157","descriptor_name":"Sorafenib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000964","descriptor_name":"Antimetabolites, Antineoplastic","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001557","descriptor_name":"Benzenesulfonates","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D002292","descriptor_name":"Carcinoma, Renal Cell","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D005467","descriptor_name":"Floxuridine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005472","descriptor_name":"Fluorouracil","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D007680","descriptor_name":"Kidney Neoplasms","qualifier_ui":"Q000473","qualifier_name":"pathology","is_major_topic":false},{"descriptor_ui":"D009536","descriptor_name":"Niacinamide","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":false},{"descriptor_ui":"D010671","descriptor_name":"Phenylurea Compounds","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011725","descriptor_name":"Pyridines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012306","descriptor_name":"Risk","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016019","descriptor_name":"Survival Analysis","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016503","descriptor_name":"Drug Delivery Systems","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018450","descriptor_name":"Disease Progression","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D023381","descriptor_name":"Endpoint Determination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:16773841","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16773841","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Oncology (Williston Park, N.Y.)","raw_type":"Journal Article"},{"id":"mag:204020518","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/16773841","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":22,"referenced_works":["https://openalex.org/W14962949","https://openalex.org/W236885201","https://openalex.org/W1507842220","https://openalex.org/W1819301164","https://openalex.org/W1979696773","https://openalex.org/W2018348203","https://openalex.org/W2041881143","https://openalex.org/W2046507292","https://openalex.org/W2053146576","https://openalex.org/W2068795211","https://openalex.org/W2074764208","https://openalex.org/W2082331198","https://openalex.org/W2095454306","https://openalex.org/W2098176107","https://openalex.org/W2105677187","https://openalex.org/W2117838810","https://openalex.org/W2120368275","https://openalex.org/W2127768463","https://openalex.org/W2171469612","https://openalex.org/W2172116130","https://openalex.org/W2305352133","https://openalex.org/W2513233117"],"related_works":["https://openalex.org/W2057594902","https://openalex.org/W2092100683","https://openalex.org/W2161816270","https://openalex.org/W2589559972","https://openalex.org/W2799699422","https://openalex.org/W2147211465","https://openalex.org/W2328136936","https://openalex.org/W2166010840","https://openalex.org/W2098364798","https://openalex.org/W1885423058"],"abstract_inverted_index":{"Several":[0],"novel":[1],"targeted":[2,148,160],"agents":[3,161],"are":[4,164],"being":[5],"tested":[6],"for":[7,158],"the":[8,50,124,175],"treatment":[9],"of":[10,18,65,70,97,126,128,174],"advanced":[11],"renal":[12],"cell":[13],"carcinoma":[14],"(RCC),":[15],"and":[16,21,62,92,119,133,154],"results":[17,173],"phase":[19,30],"I":[20],"II":[22],"trials":[23],"have":[24,121],"been":[25],"encouraging.":[26],"A":[27],"recently":[28],"completed":[29],"III,":[31],"placebo-controlled":[32],"study":[33,152],"showed":[34,76],"that":[35,100],"median":[36],"progression-free":[37],"survival":[38,83],"doubled":[39],"from":[40],"12":[41],"weeks":[42,45],"to":[43,123],"24":[44],"in":[46,81,84,136,142,162,166,178],"patients":[47,66,86,103,138],"treated":[48,146],"with":[49,147,169],"multi-kinase":[51],"inhibitor":[52],"sorafenib":[53],"(Nexavar)":[54],"(hazard":[55],"ratio":[56],"[HR],":[57],"0.44;":[58],"P":[59,89],"<":[60],".00001),":[61],"approximately":[63],"three-quarters":[64],"had":[67,104,108],"some":[68],"degree":[69],"tumor":[71,109,144],"regression.":[72],"Furthermore,":[73],"interim":[74],"analysis":[75],"an":[77,93],"estimated":[78],"39%":[79],"improvement":[80],"overall":[82],"sorafenib-treated":[85],"(HR,":[87],"0.72;":[88],"=":[90],".018)":[91],"investigator-assessed":[94],"response":[95,113,131],"rate":[96,132],"10%,":[98],"indicating":[99],"many":[101],"more":[102],"clinical":[105,134],"benefit":[106,135],"than":[107],"regression":[110],"qualifying":[111],"as":[112,141],"by":[114],"traditional":[115],"criteria.":[116],"These":[117],"data":[118],"others":[120],"added":[122],"evidence":[125],"lack":[127],"correlation":[129],"between":[130],"RCC":[137,163],"(as":[139],"well":[140],"other":[143],"types)":[145],"therapies.":[149],"Issues":[150],"surrounding":[151],"endpoints":[153],"biologic":[155],"efficacy":[156],"markers":[157],"molecular":[159],"discussed":[165],"this":[167],"article,":[168],"a":[170],"focus":[171],"on":[172],"Treatment":[176],"Approaches":[177],"Renal":[179],"Cancer":[180],"Global":[181],"Evaluation":[182],"Trial":[183],"(TARGETs).":[184]},"counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}